Prostate Cancer Coverage from Every Angle

Julie N. Graff, MD, on Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant Metastatic Castration-Resistant Disease

Posted: Monday, March 16, 2020

Julie Graff, MD, of Oregon Health & Science University and the Knight Cancer Institute, discusses whether adding pembrolizumab can overcome resistance to enzalutamide, and whether treatment with the immune checkpoint inhibitor should be continuous.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.